[go: up one dir, main page]

GT201000143A - Inhibidores de beta-lactamasa - Google Patents

Inhibidores de beta-lactamasa

Info

Publication number
GT201000143A
GT201000143A GT201000143A GT201000143A GT201000143A GT 201000143 A GT201000143 A GT 201000143A GT 201000143 A GT201000143 A GT 201000143A GT 201000143 A GT201000143 A GT 201000143A GT 201000143 A GT201000143 A GT 201000143A
Authority
GT
Guatemala
Prior art keywords
lactamasa
inhibitors
beta
botterial
proliferation
Prior art date
Application number
GT201000143A
Other languages
English (en)
Inventor
Christopher J Burns
Randy W Jackson
Goswami Rajesh
Xu Hongyu
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of GT201000143A publication Critical patent/GT201000143A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE A INHIBIDORES DE BETA-LACTAMASA LOS CUALES ACTUAN COMO INHIBIDORES DE LAS ENZIMAS DE BETA-LACTAMASA LO CUAL ES DE UTILIDAD PARA MEJORAR LA CAPACIDAD DE ACCIÓN DE CIERTAS SUSTANCIAS QUE INHIBEN LA PROLIFERACIÓN BACTERIANA TAL COMO LOS ANTIBIÓTICOS.
GT201000143A 2007-11-13 2010-05-13 Inhibidores de beta-lactamasa GT201000143A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US279707P 2007-11-13 2007-11-13

Publications (1)

Publication Number Publication Date
GT201000143A true GT201000143A (es) 2012-04-30

Family

ID=40344560

Family Applications (1)

Application Number Title Priority Date Filing Date
GT201000143A GT201000143A (es) 2007-11-13 2010-05-13 Inhibidores de beta-lactamasa

Country Status (21)

Country Link
US (2) US20100317621A1 (es)
EP (2) EP2220096A1 (es)
JP (2) JP2011504468A (es)
KR (2) KR20100109901A (es)
CN (2) CN101983203A (es)
AR (2) AR069463A1 (es)
AU (2) AU2008321443A1 (es)
BR (2) BRPI0820531A2 (es)
CA (2) CA2705393A1 (es)
CO (1) CO6331427A2 (es)
CR (1) CR11372A (es)
EA (2) EA201000774A1 (es)
EC (1) ECSP10010246A (es)
GT (1) GT201000143A (es)
IL (1) IL205205A0 (es)
MA (1) MA31874B1 (es)
MX (2) MX2010005252A (es)
TN (1) TN2010000203A1 (es)
TW (2) TW200930707A (es)
WO (2) WO2009064414A1 (es)
ZA (1) ZA201002467B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100120715A1 (en) * 2007-11-13 2010-05-13 Burns Christopher J Beta-lactamase inhibitors
US20100292185A1 (en) * 2009-05-12 2010-11-18 Burns Christopher J Beta-lactamase inhibitors
SG187757A1 (en) * 2010-08-10 2013-03-28 Rempex Pharmaceuticals Inc Cyclic boronic acid ester derivatives and therapeutic uses thereof
WO2013033461A1 (en) 2011-08-31 2013-03-07 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
JP6129203B2 (ja) * 2011-12-22 2017-05-17 アレス トレーディング ソシエテ アノニム α−アミノボロン酸誘導体、選択性免疫プロテアソーム阻害剤
CN104159587A (zh) 2012-01-06 2014-11-19 南佛罗里达大学 组合物、使用方法、以及治疗方法
SG11201406123TA (en) * 2012-03-30 2014-10-30 Cubist Pharm Inc 1,3,4-OXADIAZOLE AND 1,3,4-THIADIAZOLE β-LACTAMASE INHIBITORS
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
JP6403219B2 (ja) 2012-12-07 2018-10-10 ベナトルクス ファーマシューティカルズ，インク． ベータ−ラクタマーゼ阻害剤
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
EP2941246A4 (en) * 2013-01-04 2016-12-21 Rempex Pharmaceuticals Inc BORONIC ACID DERIVATIVES AND THEIR THERAPEUTIC USES
US9132140B2 (en) 2013-01-04 2015-09-15 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
ES2730013T3 (es) * 2013-01-10 2019-11-07 Venatorx Pharmaceuticals Inc Inhibidores de betalactamasa
US9944658B2 (en) 2013-03-14 2018-04-17 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2015171398A1 (en) * 2014-05-05 2015-11-12 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
LT3140310T (lt) 2014-05-05 2019-11-25 Rempex Pharmaceuticals Inc Boronato druskų sintezė ir jų panaudojimas
KR20170007448A (ko) * 2014-05-19 2017-01-18 렘펙스 파머수티클스 인코퍼레이티드 보론산 유도체 및 그의 치료적 용도
HRP20210693T1 (hr) * 2014-06-11 2021-06-11 VenatoRx Pharmaceuticals, Inc. Inhibitori beta-laktamaze
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CA2952968A1 (en) 2014-07-01 2016-01-07 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
SG11201702623TA (en) * 2014-10-01 2017-04-27 Merck Patent Gmbh Boronic acid derivatives
CN107074885B (zh) * 2014-10-01 2020-11-27 默克专利股份公司 硼酸衍生物
RU2017115193A (ru) * 2014-10-01 2018-11-06 Мерк Патент Гмбх Производные бороновой кислоты
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
EP3233869B1 (en) 2014-12-19 2019-09-25 Rempex Pharmaceuticals, Inc. Apparatus and continuous flow process for production of boronic acid derivatives
WO2016149393A1 (en) 2015-03-17 2016-09-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2017044828A1 (en) 2015-09-11 2017-03-16 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
US10730832B2 (en) 2016-06-21 2020-08-04 Orion Ophthalmology LLC Aliphatic prolinamide derivatives
EP3478693B1 (en) 2016-06-30 2021-07-21 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2018027062A1 (en) 2016-08-04 2018-02-08 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
IL301591B1 (en) 2017-03-06 2025-11-01 Venatorx Pharmaceuticals Inc Solid forms and combination compositions comprising a beta-lactamase inhibitor and uses thereof
EP3630783A4 (en) 2017-05-26 2021-03-03 Venatorx Pharmaceuticals, Inc. PENICILLIN-BINDING PROTEIN INHIBITORS
WO2018218190A1 (en) * 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2019009369A1 (ja) * 2017-07-06 2019-01-10 大日本住友製薬株式会社 イミン誘導体
TW201906616A (zh) * 2017-07-06 2019-02-16 日商大日本住友製藥股份有限公司 醯胺衍生物
BR112020007138B1 (pt) 2017-10-11 2023-03-21 Qpex Biopharma, Inc Derivados de ácido borônico, métodos de síntese, composição farmacêutica e uso dos mesmos
CA3097127A1 (en) 2018-04-20 2019-10-24 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
CA3098433A1 (en) * 2018-04-27 2019-10-31 Sumitomo Dainippon Pharma Co., Ltd. Oxo-substituted compound
EP3802551A4 (en) 2018-05-25 2022-03-02 Venatorx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
MA54319A (fr) * 2018-11-29 2021-10-06 Venatorx Pharmaceuticals Inc Compositions mixtes comprenant un inhibiteur de bêta-lactamase et leurs utilisations
CN110156820B (zh) * 2019-04-25 2021-06-25 四川大学 一类巯基酰胺硼酸类衍生物及其作为mbl和/或sbl抑制剂的用途
WO2020257306A1 (en) 2019-06-19 2020-12-24 Qpex Biopharma, Inc. Boronic acid derivatives and therapeutic uses thereof
CN113135944A (zh) * 2020-01-19 2021-07-20 首药控股(北京)有限公司 硼酸衍生物
EP4301466A4 (en) * 2021-03-02 2025-08-20 Univ Case Western Reserve BETA-LACTAMASE INHIBITORS AND THEIR USES

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060084592A1 (en) * 2002-09-09 2006-04-20 Trigen Limited Peptide boronic acid inhibitors
US7371729B2 (en) * 2002-09-09 2008-05-13 Trigen Limited Boronic acid salts useful in parenteral formulations
US7271186B1 (en) * 2002-12-09 2007-09-18 Northwestern University Nanomolar β-lactamase inhibitors
CA2528587A1 (en) * 2003-06-10 2005-01-20 Fulcrum Pharmaceuticals, Inc. .beta.-lactamase inhibitors and methods of use thereof
US20100120715A1 (en) * 2007-11-13 2010-05-13 Burns Christopher J Beta-lactamase inhibitors
US20100292185A1 (en) * 2009-05-12 2010-11-18 Burns Christopher J Beta-lactamase inhibitors

Also Published As

Publication number Publication date
EP2220097A1 (en) 2010-08-25
CA2705389A1 (en) 2009-05-22
KR20100109901A (ko) 2010-10-11
TW200936143A (en) 2009-09-01
CR11372A (es) 2010-09-14
WO2009064413A1 (en) 2009-05-22
CO6331427A2 (es) 2011-10-20
IL205205A0 (en) 2010-12-30
TN2010000203A1 (en) 2011-11-11
MX2010005252A (es) 2011-04-11
MA31874B1 (fr) 2010-11-01
AR069463A1 (es) 2010-01-27
ZA201002467B (en) 2011-02-23
CN101983203A (zh) 2011-03-02
CN101861324A (zh) 2010-10-13
ECSP10010246A (es) 2010-07-30
KR20100113485A (ko) 2010-10-21
MX2010005250A (es) 2010-11-05
AU2008321444A1 (en) 2009-05-22
BRPI0820531A2 (pt) 2012-07-10
WO2009064414A1 (en) 2009-05-22
US20100286092A1 (en) 2010-11-11
CA2705393A1 (en) 2009-05-22
AU2008321443A1 (en) 2009-05-22
EP2220096A1 (en) 2010-08-25
US20100317621A1 (en) 2010-12-16
TW200930707A (en) 2009-07-16
EA201000774A1 (ru) 2010-12-30
EA201000775A1 (ru) 2010-12-30
BRPI0820532A2 (pt) 2012-07-10
JP2011503181A (ja) 2011-01-27
AR069310A1 (es) 2010-01-13
JP2011504468A (ja) 2011-02-10

Similar Documents

Publication Publication Date Title
GT201000143A (es) Inhibidores de beta-lactamasa
GT201300124A (es) Inhibidores de nampt y rock
CR20110467A (es) Derivados de benzofuranilo como inhibidores de la glucoquinasa
CO7151502A2 (es) Compuestos que inhiben la actividad de catecol o- metiltransferasa
CL2012000590A1 (es) Proceso para preparar w-transaminasa (r)-selectiva.
SMT201600085B (it) Piperidin-4-il azetidin derivati come inibitori di jak1
CL2010001637A1 (es) Compuestos derivados de isoindolonas; composición farmacéutica que los comprende; y su uso como inhibidores de la quinasa mek para tratar enfermedades hiperproliferativas y/o inflamatorias tales como cáncer, artritis reumatoidea entre otras.
UY33929A (es) Compuestos de ciclohexilo tetrasustituido como inhibidores de quinasas
CR20140024A (es) Compuestos inhibidores de metaloenzimas
CR20120297A (es) Espironucleósidos uracílicos oxetánicos
ECSP12011654A (es) Derivados de 5-fluoropirimidinona
PT2536730E (pt) Compostos pirrolopirimidina enquanto inibidores de cdk4/6
NZ730134A (en) Substituted tricyclic compounds as fgfr inhibitors
CR20110046A (es) Amidofenoxiindazoles utiles como inhibidores de c-met
GT201100322A (es) Nuevos derivados de fenilimidazol como inhibidores de la enzima pde10a
JO3450B1 (ar) أشكال جرعات تحرير جديدة معدلة لمثبطات زانثين اوكسيدوريدوكتيز أو مثبطات زانثين اوكسيديز
UY33486A (es) Derivados de tetrahidro-pirido-pirimidina
BR112012018761A2 (pt) estruturas para prevenir fixação de microorganismos
CR20130616A (es) Amidas-2-piridina útiles como agonistas cb2
MA32938B1 (fr) Composes organiques
UY34216A (es) Nuevos compuestos que inhiben la actividad de la Lp-PLA2
CO6362015A2 (es) Derivados de acido 1-amino-2ciclobutiletilboronico
NI201400042A (es) 2 - tiopirimidinonas
UA106889C2 (uk) Похідні n1-ацил-5-фторпіримідинону
UY34466A (es) Proceso para estabilizar contenido bacteriano de treparaciones minerales acuosas que comprenden carbbonatos de calcio.